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Immune destruction of tumors is a  complex process that involves a  variety of 
effector mechanisms  including  cytotoxic T  cells,  macrophages,  natural  killer 
(NK) 1 cells, and humoral antibody.  Recent advances in cell hybridization tech- 
nology have focused attention  on the potential  usefulness of monoclonal anti- 
bodies (mAb)  directed against  tumor-associated antigens  as a  tool  to partially 
suppress tumor growth and thereby enhance the effectiveness of immune effec- 
tors  in  eliminating  tumors.  The  injection  of monoclonal antibody directed to 
tumor-associated  antigens  together  with  the  respective tumor  cells  into  nude 
mice may result in suppression of tumor growth (1-5). In previous experiments 
(6) we were able  to corroborate these results by using a  monoclonal antibody 
specific for a chondroitin sulfate proteoglycan preferentially expressed on human 
melanoma cells. We found that tumor suppression was markedly enhanced when 
splenocytes, in addition  to antibody,  were injected (7).  This obervation raised 
two important issues,  one regarding the mechanism by which tumor growth is 
suppressed,  the  other,  whether  this  therapy  may  be  sufficiently powerful  to 
eradicate progressively growing tumors.  In the present report, we demonstrate 
that estblished human  melanoma tumors can be eliminated by athymic (nude) 
mice by the infusion of a tumor-specific mAb and splenocytes with NK activity. 
Materials and Methods 
Tumor Cell Lines and In Vivo Tumor Rejection Assays.  The human melanoma cell line 
M21, originally provided by Dr. D. Morton, University of California, Los Angeles, was 
carried in BALB/c nude mice as a subcutaneous tumor. Progressively growing tumors 
were removed and a cell suspension was cultured in RPMI  1640 medium supplemented 
with  10%  fetal  bovine  serum  for  10  d.  These  tissue  culture-grown  M21  cells  were 
harvested and injected (7.5 ×  106 cells per mouse) subcutaneously into 6-8-wk-old BALB/ 
c athymic nude mice obtained from the nude mouse colony at the University of California, 
San  Diego.  In  some experiments, C57BL/6  nude  mice were used (Vivarium, Scripps 
Clinic and Research Foundation). 14 d after tumor inoculation, the tumors had a mean 
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volume of 80-100  mm  3.  At this  point,  mice  received intravenous injections of either 
various doses of effector cells alone, 400 #g mAb 9.2.27 alone or a combination of both. 
Tumor size was measured twice weekly with a graduated calimeter, for a total time of 6 
wk after tumor inoculation; animals with large tumors were sacrificed earlier.  Tumor- 
free animals were observed a  total of 8 wk to assure  that no tumor growth occurred. 
Tumor volume was calculated by the formula ~dld2dJ2, in which d is the diameter of the 
tumor. 
Antibodies.  mAb 9.2.27  originally produced in  this  laboratory was shown to  be  of 
IgG2a  isotype  and  directed  against  a  chondroitin  sulfate  proteoglycan preferentially 
expressed on human melanoma cells (8). IgG was purified from ascitic fluid by precipitation 
with 50% ammonium sulfate and protein A-Sepharose affinity chromatography (Sigma 
Chemical Co., St.  Louis, MO) according to the method of Ey et al.  (9). The following 
antibodies against NK cell markers were used: rabbit anti-asialo GMI antiserum (Wako 
Chemicals,  Dallas,  TX); anti-Qa5 and anti-Lyt-6.2 antisera,  kindly provided by Dr.  U. 
Hammerling (Sloan-Kettering Institute for Cancer Research, New York); and anti-NK 1.1, 
kindly provided by Dr.  S.  Pollack, (University of Washington, Seattle).  Nontoxic rabbit 
serum (Accurate Chemical & Scientific  Corporation, Westbury, NY) served as a source of 
complement. 
Treatment of Cells With Antibody and  Complement.  Mouse spleen cells  (107/ml)  were 
incubated for 30 min at room temperature with antisera diluted  1:20 to 1:50 in RPMI 
1640 medium. The cells were centrifuged; the supernatant containing unbound antibody 
was discarded;  and  the  cells  resuspended  in  complement diluted  1:10 in  RPMI  1640 
medium and incubated at 37°C for 45 min. Cells were washed twice in ice-cold medium 
and stored on ice before assay for cytotoxicity. 
In Vitro Cytotoxicity  Assays.  Mouse mononuclear splenocytes, isolated by Hypaque Ficoll 
gradient centrifugation (LSM; Litton Bionetics Inc., Charleston, SC), were used as effector 
cells  (7). BALB/c and  C57BL/6  splenocytes  served  as  normal  effector cells  whereas 
splenocytes from athymic BALB/c nu/nu mice were used as the source of T cell-deficient 
effector cells.  Splenocytes from  C57BL/6  mice with  the  homozygous beige  mutation 
(Vivarium, Scripps Clinic and Research Foundation) were used as a source of NK-deficient 
effector cells. Cloned cells with NK activity (NKB61B 10) were grown as described earlier 
(10).  In vitro cytotoxicity of splenocytes against tumor cells was assayed in a 5~Cr release 
assay as previously described (7,  10). Briefly,  tumor target cells were labeled with 51Cr 
and plated in 96-well  round-bottom tissue  culture plates (Costar, Data Packaging, Cam- 
bridge, MA) at  104 (K562, Yac-1) or at 5 ×  103 (M21) cells per well. Effector cells were 
added at  various target/effector ratios.  Replicate  wells  in  triplicate  were incubated  at 
37°C in CO2 for 4 h (K562, Yac-1) or 16 h (M21).  Cytolysis was calculated as: percent 
lysis -- [(experimental release -  spontaneous release)/(maximum release  -  spontaneous 
release)]  ×  100. 
To test for antibody-dependent, cell-mediated lysis (ADCC), we incubated tumor target 
cells with 50 ~1 per well of 9.2.27 antibody (ascites diluted  1:100) for 1 h at 37°C. The 
plates were centrifuged for 2 min, the supernatant fluids  containing unbound antibody 
were discarded, and effector cells were added. 
Results 
Melanoma  Growth in Nude Mice Is Influenced by a Component that Is Sensitive to 
Anti-asialoGM1  Serum.  In previous experiments  (7),  we had observed that the 
growth of M21  melanoma cells in nude mice can be suppressed by the simulta- 
neous injection of mAb 9.2.27  specific for M21  and splenocytes at the time of 
tumor inoculation.  We suspected that tumor suppression  was caused by a  cell- 
mediated  mechanism and  that  the  effector cells  involved were  NK cells,  since 
this  cell  type  expresses  ADCC  activity.  To  examine  the  possibility  that  M21 
melanoma growth in nude mice is  under the control of NK cells,  we rendered 
BALB/c nude mice NK deficient by injection with anti-asialo GM1  serum  (11, SCHULZ ET  AL.  1317 
12).  24  h  later,  groups  of untreated  or  anti-asialo  GM~-treated  mice  were 
inoculated subcutaneously with either 2.5 x  106 or 5 x  106 M21  cells. After 20 
d, all mice that received a  dose of 5  x  106  tumor  cells showed tumor growth. 
The mean tumor volume in this anti-asialo GM~-treated group was similar to 
the  one  in  the  untreated  animals,  i.e.,  220  mm  3 vs.  190  mm  3 (Table  I).  A 
pronounced effect of the anti-asiaio GM1 treatment was seen, however, in animals 
that received 2.5  x  106  melanoma cells:  All  five mice that were treated with 
anti-asialo  GMI  developed  tumors,  whereas  only one  of five animals  in  the 
untreated group exhibited tumor growth. This result demonstrates that treat- 
ment with anti-asialo GM~ greatly facilitates the growth of M21 melanoma cells 
in nude mice in the absence of injected antibody. Since in control experiments, 
we ascertained that injection of anti-asia|o GMt very efficiently eliminates NK 
activity, this suggested that NK cells may indeed play a role in the suppression 
of melanoma growth in nude mice. 
Progressively  Growing  M21  Tumors Are Eliminated in Nude Mice by Injection of 
mAb 9.2.27 and Mononuclear Splenocytes from Normal Mice.  We previously ob- 
served (7) that M21  melanoma tumor growth in nude mice could be inhibited 
when  mononuclear  mouse  splenocytes  and  mAb  9.2.27,  either  alone  or  in 
combination, were injected within  1 d  after tumor cell  inoculation. Based on 
these findings, we now examined whether a combination of mAb 9.2.27 and cell 
populations  with  NK  activity could  eliminate  well  established,  growing  M21 
melanoma tumors in nude mice. Groups of BALB/c nude mice (Table II) with 
2-wk-old  subcutaneous  melanoma  (mean  volume,  90  mm  3)  were  either  left 
untreated (Table II, group 1), or were injected intravenously with mAb 9.2.27 
IgG (Table II, group 2), BALB/c mononuclear splenocytes (Table II, group 3), 
or a  combination of antibody and splenocytes (Table  II, group 4).  4  wk after 
injection, 7 of 10 animals in the group that received both antibody and spleno- 
cytes (Table II, group 4) were tumor free. In contrast, all other mice exhibited 
large  tumors,  with  the  exception  of one  animal  in  the  group  that  received 
splenocytes only (Table II, group 3). The mean volume of tumors in the group 
TABLE  1 
Effect of  Anti-Asialo GM1 Injection on the Growth of  Melanoma 
Tumors in BALB/c Nude Mice 
Number of 
M21  tumor  Pretreatment  Number of  Mean tumor volume 
ceils injected  with anti-asi-  mice with  +  SE* 
subcutaneously  alo GM~*  tumors*  - 
(x  106) 
mm  ~ 
2.5  +  5/5  185 ±  19 
2.5  -  1/5  75 
5  +  5]5  220 ±  29 
5  -  5]5  190 ±  11 
*  100 el of anti-asialo GMI was injected intravenously 24 h  before tumor 
injection. 
* Data  are  for  day  21  after  tumor  inoculation.  Tumor-free  mice  were 
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TABLE II 
Effect of Different Mononuclear Splenocytes and mAb 9.2.27 on Established 
Melanoma Tumors in Nude mice 
Number of 
BALB/c  Mean tumor vol- 
Group  Injection of tumor-bearing mice*  nude mice 
with tumors  ume __. SE* 
per total* 
mm  3 
1  Control (no injection)  9/9  1,359 _+ 167 
2  mAb 9.2.27  10/10  1,285 _  151 
3  BALB/c splenocytes  j  9/10  605 __. 120 
4  BALB/c splenocytes  ~  + mAb 9.2.27  3/10  127 _+ 16 
5  mAb 9.2.27  9/9  789 +_ 130 
6  BALB/c nude splenocytes  0  8/9  504 + 87 
7  BALB/c nude splenocytes  ~ + mAb  3/9  149 +_ 41 
9.2.27 
8  Control (no injection)  8/8  1,256 _  174 
9  BALB/c nude splenocytes  0 (tumor-  7/8  960 +  178 
bearing mice) 
10  BALB/c nude splenocytes  ~  (tumor-  3/8  321 + 92 
bearing mice) + mAb 9.2.27 
* M21 tumors had a mean volume of 90 mm  3 14 d after inoculation in all experiments. 
mAb was injected at 400 #g per mouse in all experiments. 
* Data are for the results obtained 28 d after antibody and cell injection, i.e., 42 d after 
tumor inoculation. Tumor-free animals were observed for a minimum of  an additional 
28 d. 
0 2 X 107 splenocytes were injected. 
that received mAb 9.2.27  only (Table II, group 2) was nearly as great as that in 
the  untreated  control  group.  Tumors  in  the  group that received effector cells 
only (Table  II, group  3)  were  ~50%  smaller.  The  mean  volume of tumors  in 
animals injected with splenocytes and antibody (Table II, group 4) was <10% of 
that of the control tumors 28 d  after injection of splenocyte and antibody. Thus, 
the  rejection  of established  and  growing  tumors  in  nude  mice can  be accom- 
plished by the injection of antibody and mononuclear splenocytes from normal 
mice into the tumor-bearing host. 
Cells Responsible  for Antibody-induced Tumor Regression Are Present in Splenocytes 
of Tumor-free or Tumor-bearing Nude Mice.  Since nude mice lack T  cells, but the 
splenocytes from normal  mice do not,  it was possible that  the  effects observed 
were due to T  cells. To examine this possibility, we injected tumor-bearing mice 
with mononuclear splenocytes from T  cell-deficient nude mice. In groups 5, 6, 
and  7  (Table II), a  combination of mAb 9.2.27  with splenocytes from BALB/c 
nude mice eliminated the growing tumors as effectively as the cells from normal 
BALB/c mice. Six of nine animals receiving antibody and splenocytes from nude 
mice (Table II, group 7) were tumor-free 4  wk after injection and the tumors in 
the remaining animals were much smaller than  in the control group (149  +  41 
mm'~). In contrast,  eight of nine mice treated with effector cells only (Table II, 
group  6)  and  all  nine  animals injected  with antibody  only (Table  II, group  5) 
exhibited  large  tumors  of 504  +  87  and  789  +  130  mm  3,  respectively.  This SCHULZ ET  AL.  1319 
suggests that  the presence of T  cells in  normal  splenocytes is not required  for 
the elimination of tumors. Next, it was important to explore whether the effector 
cells responsible for tumor regression are also present in splenocytes of tumor- 
bearing nude mice or only in animals that are free of M21 tumors. In groups 8, 
9, and 10 (Table II), cell populations able to suppress tumor growth were derived 
from either tumor-free or tumor-bearing nude mice. This suggests that tumor- 
bearing mice contain the effector cells responsible for tumor regression, although 
possibly too few of them to cause substantial tumor regression. 
Effector Cells With NK Activity Are Responsible for Melanoma Tumor Regression in 
Nude Mice.  Two lines of evidence suggest that  NK cells are involved in tumor 
regression. First, growth of M21 tumor cells in nude mice is enhanced by in vivo 
treatment  with anti-asialo  GMa  (Table I).  Second, T  cell-deficient nude  mice 
reject the tumors in both the absence or presence of mAb 9.2.27  (Tables I and 
II). To explore this possibility further, we injected BALB/c nude mice with M21 
tumor cells as before. After  14 d, when the tumors had a  mean volume of 90 
mm 3,  mice  were  injected  with  2  ×  107  splenocytes,  some of which  had  been 
treated with anti-asialo GMI and complement. Mice also received the usual dose 
of mAb 9.2.27.  Only three of nine animals that received untreated splenocytes 
together  with  mAb  9.2.27  (Table  III,  group  2)  showed  very  limited  tumor 
growth after 4  wk.  In contrast,  all  mice that  received splenocytes treated with 
anti-asialo  GM~ and complement showed substantial  tumor growth (Table III, 
group 3), essentially the same as that of the control group (Table III, group  1). 
These  results  indicate  that  the  effector cells responsible for tumor  regression 
carry the asialo GM~ cell surface antigen, and suggest that they may be NK cells. 
To further test this conclusion, splenocytes from genetically NK-deficient mice 
carrying  the  homozygous  beige  mutation  (13,  14)  were  also  transplanted  in 
tumor-bearing hosts. Specifically, C57BL/6 nude mice with progressively grow- 
ing M21 tumors were injected with mAb 9.2.27 together with splenocytes from 
either normal C57BL/6 mice or C57BL/6 beige mice. None of the animals that 
received normal C57BL/6 splenocytes and antibody showed tumor growth after 
4 wk (Table III, group 5), as was expected from the experiments with splenocytes 
from normal BALB/c mice (Table II, group 4). In contrast, animals that received 
mAb 9.2.27 and splenocytes from C57BL/6 beige mice experienced high tumor 
incidence (Table III, group 6), showing that the cell type responsible for tumor 
rejection  is  absent  in  beige  mice  and  is  therefore  likely  associated  with  NK 
activity. To further substantiate the conclusion that NK cells are responsible for 
tumor  regression,  we injected  C57BL/6 nude  mice  that  had  established  M21 
tumors with the cloned NK cell line  NKB61B10. In groups 7, 8, and 9 (Table 
III), a single dose of 2 ×  l0 s NKB61B10 cells, i.e., a dose only 1A0th that of the 
splenocytes used in  the other experiments,  resulted  in a  strong suppression  of 
tumor size (~70%), particularly  in those mice that  received antibody as well as 
NK cells. However, tumors were not completely eliminated, probably because of 
the uncommonly large size of the tumors at the onset of the experiment (mean 
volume, 185 mm3). 
M21 Melanoma Cells Are Lysed by Effector Cells with NK Activity in the Presence 
ofmAb  9.2.27.  The  experiments  so far presented  point to the importance  of 
the presence of both effector cells with NK activity and specific antibody for the 1320  MELANOMA  REJECTION  BY  ANTIBODY-DIRECTED EFFECTORS 
TABLE  III 
Evidence for NK Cells as Effectors in Suppression of Tumor Growth 
Number of 
nude mice  Group  Injection  of tumor-bearing mice  with tumors  Strain 
per total 
Mean tumor vol- 
ume + SE 
1  Control (no injection)  9/9  BALB/c 
2  BALB/c nude splenocytes  + mAb  3/9  BALB/c 
9.2.27 
3  BALB/c nude splenocytes  treated  9/9  BALB/c 
with anti-asialo GM1 + C + mAb 
9.2.27 
mm ~ 
930 + 204 
149 + 41 
978 + 126 
4  mAb 9.2.27*  8/8  C57BL/6  741 + 83 
5  C57BL/6 splenocytes  + mAb  0/10  C57BL/6  -- 
9.2.27* 
6  C57BL/6 beige splenocytes  + mAb  8/9  C57BL/6  634 _ 292 
9.2.27* 
7  Control  (no injection)*  7/7  C57BL/6  2,160 + 292 
8  NKB61B10*  6/6  C57BL]6  1,060 + 167 
9  NKB61B10  + mAb 9.2.27*  6/6  C57BL/6  610 + 181 
Data are given for day 28 after antibody and cell injection, i.e., 42 d after tumor  inoculation. 
Tumor-free animals were observed for an additional 28 d. 
* Mean tumor size at the onset of the experiments was 90 mms at day 14 after tumor inoculation. 2 
x  107 splenocytes  were injected. 
* Mean tumor size at the onset of the experiment was 185 mms at day 14 after tumor inoculation. 2 
x  106 NKB61B10 were injected. 
elimination of an established tumor. Since it is known (15-19) that NK cells are 
able to perform ADCC, we examined whether M21  melanoma cells were lysed 
by  mAb  9.2.27  and  effector  cells  with  NK  activity.  To  this  end,  BALB/c 
mononuclear splenocytes, mixed with M21  melanoma target cells, were assayed 
for their  cytolytic activity in  the  absence and presence of mAb 9.2.27  in  5~Cr 
release  assays.  We  found  that  the  effector  cells  caused  25%  cytolysis  in  the 
absence of antibody (Fig.  1).  After preincubation of the target cells with  mAb 
9.2.27, the cytotoxicity increased to 38%. The same effector cell population also 
showed lysis of the NK-sensitive YAC-1 target. The elimination of cells with NK 
activity by pretreatment of splenocytes with anti-asialo GM~  serum and comple- 
ment resulted  in a  marked reduction of cytotoxicity against M21  cells,  both in 
the presence and absence of mAb 9.2.27. At the same time, the anti-asialo GM1- 
treated effector cells were no longer able to lyse YAC-1  target cells,  indicating 
that NK activity was indeed eliminated by this treatment. To further substantiate 
the  conclusion  that  cells  with  NK  activity  were  the  effectors  in  this  ADCC 
reaction, we used other antibodies that are specific for NK cells,  i.e.,  anti-Qa5 
and anti-NK1.1  (20-24). In addition, effector cells from NK-deficient C57BL/6 
beige mice (13,  14) were tested.  The data in  Fig. 2  demonstrate that C57BL/6 
mononuclear  splenocytes  mediated  cytotoxic activity of the  same  magnitude, 
against M21  and YAC-1 target cells, as did BALB/c effector cells. Treatment of 
C57BL/6 effector cells with anti-Qa5 and anti-NK 1.1, but not with anti-Lyt-6.2, Effector  Cells 
BALB/c 
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FIGURE  1.  Effect of pretreatment  of BALB/c mononuclear effector cells with anti-asialo 
GM~ and complement on cytotoxic reactivity against M21 melanoma and Yac-I target cells in 
51Cr release assays.  (Shaded bar) M21  target cells preincubated with mAb 9.2.27; (open bar) 
effector cells alone. 
resulted  in  a  complete suppression  of cytotoxicity of both  YAC-1  and  M21, 
regardless of the presence of mAb 9.2.27.  In addition, C57BL/6 beige effector 
cells  did  not  mediate  an  efficient cytotoxicity in  these  assays.  These  results 
strongly support the conclusion that cells with NK activity are indeed responsible 
for the antibody-dependent and antibody-independent cytolysis of M21  tumors. 
Discussion 
Our results show that the eradication of well established melanomas in athymic 
mice  using  tumor-specific antibody  requires  the  simultaneous  injection  of a 
relatively large  number of mononuclear splenocytes.  Neither splenocytes nor 
antibody alone achieved significant tumor regression. The cells responsible for 
tumor  elimination  are  probably  cells  with  NK  activity:  they  are  present  in 
splenocytes of T  cell-deficient nude mice, and cloned NK cells are similarly able 
to suppress tumor growth. Moreover, the effector cells were absent in splenocytes 
of NK-deficient beige mice and could be eliminated by injection of mice with 
anti-asialo GM1  antiserum, which is known to eliminate NK activity. Previous 
studies (20, 25-27) suggested that there may be a degree of heterogeneity within 
mouse NK cells, not only in cell surface markers but also in responsiveness to 
the regulatory influences of interferon and interleukin 2. It is therefore possible 
that the ceils responsible for tumor regression are heterogeneous. Our observa- 
tion that clone NKB61B10 was not quite as effective as normal splenocytes may 
support this possibility, especially since this clone very effectively prevents the 
rejection of bone marrow allografts and protects against radiation-induced leu- 
kemia (28).  A  more precise definition of the cell type responsible for tumor 
regression would have been possible using other NK-specific reagents, like anti- 1322  MELANOMA  REJECTION  BY  ANTIBODY-DIRECTED  EFFECTORS 
%  Cr st  Release 
Ef lector  Cells 
Normal 
C57  BL/6 
10  20  30  40  50 
|  !  |  !  | 
Beige 
C57  BL/6 
Normal  C57  BL /6 
treated  with  anti-Qa-5 ÷ C 
Normal  C57  BL/6 
treated  with  anti- NK-I.1  + C 
.M2Z 
Normal  C57  BL / 6 
treated  with  anti o Lyt - 6.2 ÷ C 
Normal 
C57  BL 1 6 
Beige 
C57  BL/6 
Normal  C57  BL  /6 
treated  with  anti- Qa- 5 + C 
Normal  C57  BL  /6 
treated  with  anti-NK-11  +C 
Normal  C57  BL /  6 
treated  with  anti-Lyt-6.2+C 
!  !  !  | 
I  ; 
FIGURE 2.  Comparison of cytotoxic effects against M21  human melanoma cells and Yac-1 
target cells by mononuclear effector cells obtained from normal C57BL/6 mice, pretreated 
with anti-Qa5, anti-NK1.1, and anti-Lyt-6.2, as well as by effector cells obtained from C57BL/ 
6 beige mice. (Shaded bar) M21 target cells preincubated with mAb 9.2.27; (open bar) effector 
cells alone. 
Qa5  and  anti-NKl.1  antisera,  which are  reactive with  C57BL/6  NK cells but 
have little reactivity with other cell types, like T  cells, natural cytotoxic cells, or 
monocytes (20, 21, 23, 27, 29). The limited amounts of these antisera available, 
however, precluded their in vivo use. We therefore demonstrated in vitro that 
both antibody-dependent and antibody-independent  cell-mediated lysis of M21 
melanoma targets is inhibited not only by anti-asialo  GM~ but also by anti-Qa5 
and anti-NK1.1.  The ability of anti-NK 1.1  to eliminate  NK cells in vivo and in 
vitro had  been previously demonstrated  by the work of Pollack (23,  24).  Our 
results, therefore, strongly support the conclusion that both, antibody-dependent 
and antibody-independent in vitro lysis and in vivo elimination of tumor ceils are 
functions of effector cells with NK activity. This conclusion is in full agreement 
with previous results demonstrating  that cloned murine cell lines (10) with NK 
activity not only restored the ability of NK-deficient mice to suppress the growth 
of the  murine  melanoma  B16,  but also decreased  the  incidence  of radiation- 
i 
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induced leukemias (28).  Moreover, the ability to reject bone marrow grafts is 
also restored by injection of cloned NK cells into  NK-deficient mice. Interest- 
ingly, the specificity of marrow graft rejection depends on IgG antibody present 
in the graft recipient and specific for the bone marrow transplant (28, 30). The 
acute  rejection  of bone  marrow  grafts  by  NK  cells  is,  therefore,  due  to  an 
antibody-dependent cytotoxic reaction,  very similar  to  the  rejection  of M21 
melanoma tumors induced by mAb 9.2.27 and NK cells. 
It is interesting that the injection of the tumor-specific mAb 9.2.27 into tumor- 
bearing nude mice is not sufficient to ca'use optimal tumor rejection, especially 
since such animals have a high level of NK activity. The explanation we favor is 
that the number of NK cells in the host is insufficient to cause tumor rejection. 
Another possibility is that host NK cells are blocked in their interaction with the 
mAb by circulating serum factors that inhibit their action; however, our experi- 
ments with spleen cells from tumor-bearing mice argue against this possibility. It 
may be important that antibody and effector cells be injected simultaneously so 
that  the  antibody  can  bind  to  the  effectors,  thereby  "arming"  them.  This 
antibody-effector cell interaction may facilitate the targeting of effector cells to 
the tumor in a  more efficient way. Previously (7), we noticed that the simulta- 
neous injection of tumor cells and effector cells armed with antibody by conju- 
gation with polyethylene glycol very efficiently suppresses in vivo tumor growth. 
Taken together, these results may suggest a novel approach for the treatment of 
tumors that makes use of two powerful tools, tumor-specific mAb and cytolytic 
effector lymphocytes. 
Summary 
The simultaneous injection of monoclonal antibody 9.2.27, directed against a 
chondroitin sulfate proteoglycan preferentially expressed on human melanoma 
cells, and 2 x  107 mononuclear splenocytes, eradicated established, progressively 
growing human melanoma tumors in nude mice. Neither splenocytes nor anti- 
body alone achieved significant tumor regression. The cells responsible for tumor 
elimination are most likely natural killer (NK) cells: they are present in spleno- 
cytes of T  cell-deficient nude mice, and cloned cells with NK activity are able to 
suppress tumor growth. Moreover, splenocytes treated with anti-asialo GM~ and 
complement or harvested from NK-deficient C57BL/6 beige mice did not cause 
tumor  rejection.  Furthermore,  treatment of BALB/c  nude  mice just  before 
injection with anti-asialo GM1 antiserum, which is known to eliminate NK activity 
in vivo, resulted in better tumor growth. In addition, evidence is presented that 
cells with NK activity are probably the effectors responsible for melanoma target 
cell lysis  in vitro:  Antibody-dependem and -independent cell-mediated lysis of 
M21  melanoma cells was suppressed when splenocytes were preincubated with 
J  complement and antibodies specific for cell surface antigens of NK cells, i.e., 
anti-asialo GM~, anti-Qa5, and anti-NKl.1.  Moreover, splenocytes of C57BL/6 
beige mice were not able to lyse M21 cells in vitro. These results strongly support 
the conclusion that cells with NK activity are indeed responsible for the antibody- 
dependent destruction of M21  melanoma cells in vivo and in vitro. 1324  MELANOMA  REJECTION  BY  ANTIBODY-DIRECTED  EFFECTORS 
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